Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS

$125m Upfront For InnoCare

BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.

Biogen has paid $125m upfront to get its hands on Chinese company InnoCare’s orelabrutinib, one of a number of promising BTK inhibitors which could transform multiple sclerosis (MS) treatment.

While Biogen is in the news for the ongoing controversy around its newly approved Alzheimer’s drug Aduhelm (aducanumab), it is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.